# A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma

> **NCT06556199** · PHASE1,PHASE2 · RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 38 (estimated)

## Conditions studied

- Relapsed/Refractory Primary Central Nervous System Lymphoma

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Temozolomide
- **DRUG:** Anti-PD-1 monoclonal antibody

## Key facts

- **NCT ID:** NCT06556199
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-31
- **Primary completion:** 2026-08-31
- **Final completion:** 2028-08-31
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2025-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06556199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06556199, "A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06556199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*